4TEEN4 Receives U.S. FDA Fast Track Designation for Invobenitug in Cardiogenic Shock

The U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to invobenitug (procizumab) for the treatment of cardiogenic shock.